Spero Therapeutics

86 articles with Spero Therapeutics

• Spero Therapeutics Hosting Key Opinion Leader Call on Oral Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections

  9/24/2020

  Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced it will host a key opinion leader (KOL) call on oral tebipenem HBr for the treatment of complicated urinary tract infections on Wednesday, September 30, 2020

• Spero Therapeutics to Present at Investor Conferences in September

  9/15/2020

  Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will provide a corporate update at the following investor conferences in September

• Spero Therapeutics Announces Pricing of Securities Offering - Sep 11, 2020

  9/11/2020

  Spero Therapeutics, Inc. announced the pricing of its previously announced underwritten public offering of 4,785,000 shares of its common stock and 3,215,000 shares of its non-voting Series D Convertible Preferred Stock.

• 

  Biotech IPOs: Intra-Cellular Therapies, 10x Genomics and Spero Therapeutics

  9/11/2020

  It was a busy week for biopharma, biotech and medical device initial public offerings (IPOs). Here’s a look.

• Spero Therapeutics Announces Proposed Public Offering

  9/9/2020

  Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multidrug-resistant (MDR) bacterial infections and rare diseases, today announced that it has commenced an underwritten public offering of 8,000,000 shares of common stock in the aggregate, consisting of an offering of shares of common stock (the “

• Spero Therapeutics Announces Positive Topline Results from its Phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute Pyelonephritis

  9/8/2020

  Pivotal Phase 3 clinical trial of oral tebipenem HBr met primary endpoint, demonstrating statistical non-inferiority versus intravenous ertapenem in patients with complicated urinary tract infection and acute pyelonephritis

• Spero Therapeutics Announces FDA Acceptance of IND Application for SPR720

  8/31/2020

  Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections, today announced the acceptance by the U.S. Food and Drug Administration (FDA) of Spero’s Investigational New Drug application (IND) for SPR720,

• Spero Therapeutics Announces Second Quarter 2020 Operating Results and Provides Business Update

  8/6/2020

  Top-line data for Phase 3 ADAPT-PO trial evaluating oral tebipenem HBr in complicated urinary tract infection expected in 3Q20

• Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 31, 2020

  7/31/2020

  Spero Therapeutics, Inc. announced that on July 31, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 22,000 shares of its common stock to two new employees under the Spero Therapeutics, Inc.

• Spero Therapeutics to Provide Business Update and Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020

  7/29/2020

  Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on August 6, 2020 at 4:30 p.m.

• Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 30, 2020

  6/30/2020

  Spero Therapeutics, Inc. announced that on June 30, 2020, the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 40,000 shares of its common stock to five new employees under the Spero Therapeutics, Inc.

• Spero Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference

  6/1/2020

  Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will provide a corporate update at the Jefferies 2020 Virtual Healthcare Conference

• Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 01, 2020

  6/1/2020

  Spero Therapeutics, Inc. announced that on May 29, 2020, the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 29,500 shares of its common stock to four new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan.

• Spero Therapeutics Announces First Quarter 2020 Operating Results and Provides Business Update

  5/8/2020

  Tebipenem HBr Phase 3 trial enrollment complete with top-line data expected in the third quarter of 2020 SPR720 Phase 2a NTM trial initiation planned for the second half of 2020 Conference call and live webcast at 10:00 a.m. EDT today CAMBRIDGE, Mass., May 08, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-

• Spero Therapeutics Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial (ADAPT-PO) of Oral Tebipenem HBr versus Intravenous Ertapenem for the Treatment of Complicated Urinary Tract Infection

  5/5/2020

  Spero Therapeutics, Inc. announced the completion of patient enrollment in its Phase 3 clinical trial, ADAPT-PO, of tebipenem HBr for the treatment of complicated urinary tract infection and acute pyelonephritis.

• Spero Therapeutics to Provide Business Update and Report First Quarter 2020 Financial Results on Friday, May 8, 2020

  5/4/2020

  Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on May 8, 2020 at 10:00 a.m. EDT to report its first quarter 2020 financial results and provide an update on its b

• Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 30, 2020

  4/30/2020

  Spero Therapeutics, Inc. announced that on April 30, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 21,000 shares of its common stock to three new employees under the Spero Therapeutics, Inc.

• Spero Announces Appointment of Scott Jackson to its Board of DirectorsSpero brings significant commercial leadership and business development experience to its Board of Directors with appointment of pharmaceutical veteran, Scott Jackson

  4/16/2020

  Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, announced the appointment of Scott Jackson to its Board of Directors.

• Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 31, 2020

  3/31/2020

  Spero Therapeutics, Inc. announced that on March 31, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 31,500 shares of its common stock to five new employees under the Spero Therapeutics, Inc.

• Spero Therapeutics Announces Fourth Quarter and Full-Year 2019 Operating Results and Provides Pipeline Update2020 catalysts include tebipenem HBr pivotal Phase 3 top-line cUTI data in 3Q20 and SPR720 Phase 2a NTM trial initiation in 2H20

  3/16/2020

  Spero Therapeutics, Inc.  today announced financial results for the fourth quarter and full-year ended December 31, 2019 and provided a pipeline update.